BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. OraSure’s presentation is scheduled for Thursday, January 16, 2025 at 9:00 a.m. PT. A live webcast and replay of the... Read More

BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Tuesday, January 7th by OraSure Technologies, Inc. (NASDAQ: OSUR), please note that the first sentence of the release (read "OraQuick ® HIV Self-Test that will increase access to HIV testing for adolescents.") is incomplete. The corrected release follows: OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in... Read More

BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick ® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick ® HIV Self-Test. Previously the test was approved for use in those 17 and older. According to the most recent data available from the Centers for Disease Control & Prevention, it is... Read More

BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure’s innovation pipeline with the addition of... Read More

BETHLEHEM, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and... Read More

BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference: Stephens Annual Investment Conference on Wednesday, November 20, with a Q&A session scheduled for 1 p.m. ET A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at... Read More

Q3 GAAP EPS of $(0.06); Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing business to focus on markets with attractive growth opportunities BETHLEHEM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care... Read More

BETHLEHEM, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc . (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2024 financial results and certain business developments for 5 p.m. ET on November 6, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations . Please... Read More

BETHLEHEM, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced the election of Jack Kenny to its Board of Directors, effective September 9, 2024. With the addition of Mr. Kenny, OraSure’s Board of Directors currently has seven members. Mr. Kenny is the former Chief Executive Officer for Meridian... Read More

Q2 GAAP EPS of $(0.01); Q2 Non-GAAP EPS of $0.07 OraQuick® HCV Self-test is the first globally to earn WHO pre-qualification Strong momentum with Syphilis Health Check™ launch Expanding Sample Management applications into saliva-based liquid biopsy BETHLEHEM, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions,... Read More

BETHLEHEM, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2024 financial results and certain business developments for 5 p.m. ET on August 6, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations . Please... Read More

BETHLEHEM, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced its support of HIV testing initiatives taking place across the nation in recognition of National HIV Testing Day, held each year on June 27th. These testing initiatives will help encourage thousands of people across the U.S. to get... Read More

Q1 GAAP EPS of $(0.05); Q1 Non-GAAP EPS of $0.04 Restructuring initiatives expected to result in $15 million of annualized expense reductions once fully implemented and position OraSure to achieve cash flow breakeven for core business by end of 2024 Delivered initial orders for Syphilis Health Check™ as part of our distribution agreement with Diagnostics Direct BETHLEHEM, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- OraSure... Read More

BETHLEHEM, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m. ET on Wednesday, May 8, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations.... Read More

Q4 GAAP EPS of $0.27; Q4 Non-GAAP EPS of $0.22 Grew cash balance to $290.4 million as of December 31, 2023 Enters U.S. Syphilis testing market via strategic distribution agreement with Diagnostics Direct BETHLEHEM, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical... Read More

BETHLEHEM, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2023 financial results and certain business developments for 5 p.m. ET on Tuesday, Feb. 27, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations.... Read More

The relationship expands OraSure’s innovation pipeline with access to a broad portfolio of key Sapphiros products in development. Distribution of Sapphiros’ products is expected to accelerate OraSure’s core revenue growth rate beginning in 2025. BETHLEHEM, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and... Read More

BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the company is scheduled to participate in the following investor conferences: Stephens Annual Investment Conference on Wednesday, November 15, with a Q&A session scheduled for 2 p.m. ET... Read More

Q3 GAAP EPS of $0.15; Q3 Non-GAAP EPS of $0.27 Grew cash balance to $224.9 million as of September 30, 2023 BETHLEHEM, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc . (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three months ended September 30, 2023. “We... Read More

BETHLEHEM, Pa., Oct. 23, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2023 financial results and certain business developments for 5:00 pm ET on Tuesday, November 7, 2023. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations.... Read More

InteliSwab® test revenue of $47.5 million in Q2 Q2 Core revenue of $37.9 million grew 4% sequentially and 3% year-over-year Q2 GAAP EPS of $(0.07); Q2 Non-GAAP EPS of $0.09 Grew cash balance to $185.9 million as of June 30, 2023 InteliSwab® orders are expected to generate at least $70 million of revenue in second half of 2023 On track to achieve operating cash flow breakeven on core business by end of 2024 BETHLEHEM, Pa.,... Read More

BETHLEHEM, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 second quarter financial results and certain business developments for 5:00 pm ET on Thursday, August 3, 2023. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations.... Read More

BETHLEHEM, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced today the election of Robert W. McMahon, CMA, MBA, to the Company’s Board of Directors, effective July 31, 2023. Including McMahon, the company’s Board of Directors has seven members. Mr.... Read More

BETHLEHEM, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and at-home diagnostic testing, as well as non-invasive self-sampling technologies and microbiome-focused biocomputational solutions, announced today that a major health economics study featuring its Colli-Pee ® device has been published in the biomedical journal “BMJ Open.” This study, conducted by... Read More

InteliSwab ® test revenue of $118.3 million in Q1, up 33% sequentially; Company delivers cost savings and begins to taper InteliSwab ® test production and expenses Gross margins increase 200 basis points sequentially despite mix/pricing headwinds Signs three new molecular partnerships supporting cancer diagnostics, women’s health testing, and microbiome services Q1 GAAP EPS of $0.37; Non-GAAP EPS of $0.47 Improved cash... Read More

BETHLEHEM, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 first quarter financial results and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, May 10, 2023. May 10, 2023 schedule: 4:05 p.m. ET – 2023 first quarter financial results press release will be distributed. Prior to the call - To participate... Read More

InteliSwab ® revenue of $88.9 million in Q4, up 12% sequentially; wins two new federal government contracts extending the tail on InteliSwab ® revenue Signs a deal with Quest Diagnostics Genomic Sequencing Services for saliva collection kits Q4 GAAP EPS of $0.21; Non-GAAP EPS of $0.36 Announces restructuring expected to result in operating expense savings of $15 million to be fully implemented by June 2023; targets achieving... Read More

BETHLEHEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, February 14, 2023. February 14, 2023 schedule: 4:05 p.m. ET – 2022 fourth quarter financial results press release will be distributed. Prior to the call - To... Read More